MD1531Z - Phytotherapeutic food supplement antiSARS-CoV-2 - Google Patents
Phytotherapeutic food supplement antiSARS-CoV-2 Download PDFInfo
- Publication number
- MD1531Z MD1531Z MDS20200126A MDS20200126A MD1531Z MD 1531 Z MD1531 Z MD 1531Z MD S20200126 A MDS20200126 A MD S20200126A MD S20200126 A MDS20200126 A MD S20200126A MD 1531 Z MD1531 Z MD 1531Z
- Authority
- MD
- Moldova
- Prior art keywords
- cov
- aerial part
- phytotherapeutic
- root
- food supplement
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 21
- 235000011330 Armoracia rusticana Nutrition 0.000 claims abstract description 10
- 240000003291 Armoracia rusticana Species 0.000 claims abstract description 10
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 10
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 10
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 10
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 10
- 241001426527 Rhaponticum Species 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 7
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 7
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 7
- 241000241413 Propolis Species 0.000 claims abstract description 7
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 7
- 229940069949 propolis Drugs 0.000 claims abstract description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000020234 walnut Nutrition 0.000 claims abstract description 7
- 235000019441 ethanol Nutrition 0.000 claims abstract description 5
- 239000008213 purified water Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 240000007049 Juglans regia Species 0.000 claims abstract description 4
- 244000067505 Xanthium strumarium Species 0.000 claims abstract description 4
- 239000012675 alcoholic extract Substances 0.000 claims abstract description 3
- 238000000605 extraction Methods 0.000 claims abstract description 3
- 240000006891 Artemisia vulgaris Species 0.000 claims description 9
- 241000758789 Juglans Species 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- 235000004355 Artemisia lactiflora Nutrition 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 18
- 241001678559 COVID-19 virus Species 0.000 abstract description 17
- 239000003963 antioxidant agent Substances 0.000 abstract description 11
- 230000003308 immunostimulating effect Effects 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 239000013589 supplement Substances 0.000 description 9
- 108010053070 Glutathione Disulfide Proteins 0.000 description 6
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 6
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 6
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 5
- 108010087806 Carnosine Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 5
- 229940044199 carnosine Drugs 0.000 description 5
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000010470 Ageusia Diseases 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 235000001466 Ribes nigrum Nutrition 0.000 description 2
- 241001312569 Ribes nigrum Species 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000011483 Ribes Nutrition 0.000 description 1
- 241000220483 Ribes Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- CKGWFZQGEQJZIL-UHFFFAOYSA-N amylmetacresol Chemical compound CCCCCC1=CC=C(C)C=C1O CKGWFZQGEQJZIL-UHFFFAOYSA-N 0.000 description 1
- 229960005213 amylmetacresol Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000614 rib Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Invenţia se referă la industria alimentară, sanocreatologie şi medicină, în special la un supliment alimentar fitoterapeutic, biologic activ, care posedă activitate antioxidantă, imunostimulatoare cu inhibarea virusului SARS-CoV-2. The invention relates to the food industry, sanocreatology and medicine, in particular to a phytotherapeutic, biologically active food supplement, which possesses antioxidant, immunostimulating activity with inhibition of the SARS-CoV-2 virus.
Elaborarea noilor fitocompoziţii biologic active pe bază de materii prime locale, cu efect antiviral, imunostimulator cu inhibarea virusului SARS-CoV-2, este o sarcină prioritară a ştiinţei moderne împotriva unei pandemii la scară planetară şi are drept scop îmbunătăţirea sănătăţii şi menţinerea vieţii locuitorilor nu numai în Republica Moldova, dar şi în alte regiuni ale globului. The development of new biologically active phytocompositions based on local raw materials, with antiviral, immunostimulating effect and inhibition of the SARS-CoV-2 virus, is a priority task of modern science against a pandemic on a global scale and aims to improve the health and maintain the lives of residents not only in the Republic of Moldova, but also in other regions of the globe.
Este cunoscută utilizarea compoziţiei farmaceutice care conţine: alcool 2,4-dichlorbenzyl în combinaţie cu amilmetacrezolom destinată profilaxiei şi tratamentului infecţiilor virale provocate de coronavirusul SARS cu fenotipul Urbani. Această compoziţie se poate afla atât în stare lichidă, cât şi în stare solidă [1]. It is known to use a pharmaceutical composition containing: 2,4-dichlorobenzyl alcohol in combination with amylmetacresol for the prophylaxis and treatment of viral infections caused by SARS coronavirus with the Urbani phenotype. This composition can be in both liquid and solid state [1].
Dezavantajul acestei compoziţii, constă în faptul că ingredientele ei reprezintă antiseptice şi au acţiune numai la nivel local, totodată această compoziţie nu are efect în cazul coronavirusului SARS-CoV-2. The disadvantage of this composition is that its ingredients are antiseptics and have action only locally, and this composition has no effect on the SARS-CoV-2 coronavirus.
Mai este cunoscută compoziţia care conţine extract apos din frunze şi tulpini de coacăză neagră, care face parte din genul Ribes şi anume Ribes nigrum L., destinat tratamentului infecţiilor virale provocate de rinoviruşi, adenoviruşi, coronaviruşi, retroviruşi şi gripă, totodată a fost observat şi efectul de a inhiba infecţia virală provocată de HIV1 şi HIV2 şi care posedă proprietăţi de inhibare a coronaviruşilor [2]. The composition containing aqueous extract from blackcurrant leaves and stems, which is part of the Ribes genus, namely Ribes nigrum L., is also known, intended for the treatment of viral infections caused by rhinoviruses, adenoviruses, coronaviruses, retroviruses and influenza, and the effect of inhibiting viral infection caused by HIV1 and HIV2 has also been observed, and it possesses properties that inhibit coronaviruses [2].
Dezavantajul acestei compoziţii constă în faptul că nu are efect în cazul coronavirusului SARS-CoV-2. The disadvantage of this composition is that it has no effect on the SARS-CoV-2 coronavirus.
Mai este cunoscută compoziţia destinată tratamentului SARS-CoV-2, care include, în %: 43-44 favipiravir micronizat cu o dimensiune a particulelor de 40-50 microni, 5,5-6,0 croscarmeloză sodică, 4,8-5,0 povidonă, 0,6-0,8 stearat de magneziu, 0,5-0,7 dioxid de siliciu coloidal, 2,5-2,7 înveliş de film, iar restul este celuloză microcristalină, durata de tratament cu acest remediu, constituie în medie 10 zile [3]. The composition intended for the treatment of SARS-CoV-2 is also known, which includes, in %: 43-44 micronized favipiravir with a particle size of 40-50 microns, 5.5-6.0 croscarmellose sodium, 4.8-5.0 povidone, 0.6-0.8 magnesium stearate, 0.5-0.7 colloidal silicon dioxide, 2.5-2.7 film coating, and the rest is microcrystalline cellulose, the duration of treatment with this remedy is on average 10 days [3].
Dezavantajul acestei compoziţii constă în faptul că reprezintă un remediu medicamentos care se prescrie numai prin reţetă, iar pentru a obţine reţeta trebuie de vizitat medicul într-o instituţie medicală, totodată persoanele care suferă de SARS-CoV-2 sunt o sursă de infecţie, care pot răspândi infecţia în instituţiile medicale şi în rândurile medicilor, în acelaşi timp costul unei cutii este de 145 Euro, ceea ce face dificilă accesibilitatea la tratament a persoanelor social vulnerabile şi nu are efect antioxidant, iar în cazul infectării cu SARS-CoV-2 creşte intoxicaţia, iar efectul antioxidant este vital necesar. Administrarea acestui remediu poate duce la reacţii adverse ca: leucopenie, creşterea ALAT şi ASAT, a nivelului de trigliceride şi de acid uric, prin urmare, administrarea acestui remediu poate fi contraindicată persoanelor ce suferă de podagră, insuficienţă cardiacă şi hepatică. The disadvantage of this composition is that it is a medicinal remedy that is prescribed only by prescription, and to obtain the prescription you must visit a doctor in a medical institution, at the same time, people suffering from SARS-CoV-2 are a source of infection, who can spread the infection in medical institutions and among doctors, at the same time the cost of a box is 145 Euros, which makes it difficult for socially vulnerable people to access treatment and it has no antioxidant effect, and in the case of infection with SARS-CoV-2, intoxication increases, and the antioxidant effect is vitally necessary. The administration of this remedy can lead to adverse reactions such as: leukopenia, increased ALAT and ASAT, triglyceride and uric acid levels, therefore, the administration of this remedy may be contraindicated for people suffering from gout, heart and liver failure.
Problema tehnică a invenţiei constă în lărgirea gamei de suplimente alimentare, care posedă efect antioxidant prin inhibarea radicalilor liberi cu ulterioara reducere a acestora, şi imunostimulator, cu inhibarea virusului SARS-CoV-2, bazat numai pe ingrediente fitoterapeutice, care poate fi livrat persoanelor fără reţetă, ar diminua semnificativ termenii de însănătoşire şi nu ar provoca reacţii adverse. Dat fiind faptul că bolnavii infectaţi cu SARS-CoV-2 suferă de un şir de patologii asociate, aceşti factori devin primordiali în tratamentul acestei maladii. The technical problem of the invention consists in expanding the range of food supplements, which have an antioxidant effect by inhibiting free radicals with their subsequent reduction, and immunostimulatory, with inhibition of the SARS-CoV-2 virus, based only on phytotherapeutic ingredients, which can be delivered to people without a prescription, would significantly reduce the terms of recovery and would not cause adverse reactions. Given the fact that patients infected with SARS-CoV-2 suffer from a number of associated pathologies, these factors become paramount in the treatment of this disease.
Esenţa invenţiei constă în faptul, că suplimentul alimentar fitoterapeutic conţine extract alcoolic din: partea aeriană de pelin, partea aeriană de cornet, rădăcină de maral, coajă de nucă, rădăcină de hrean, partea aeriană de leuştean şi propolis, obţinut la extragerea cu alcool etilic de 96,4% vol. în raport respectiv de 1:(4-5), timp de 15-21 de zile, precum şi apă purificată, restul, până la atingerea unei tării de 32-35% vol., ingredientele fiind luate în următorul raport, în % mas: The essence of the invention lies in the fact that the phytotherapeutic food supplement contains alcoholic extract of: the aerial part of wormwood, the aerial part of cornel, maral root, walnut shell, horseradish root, the aerial part of lovage and propolis, obtained by extraction with 96.4% vol. ethyl alcohol in the respective ratio of 1:(4-5), for 15-21 days, as well as purified water, the rest, until reaching a strength of 32-35% vol., the ingredients being taken in the following ratio, in % mass:
partea aeriană de pelin, Artemisia vulgaris 15±3 partea aeriană de cornet, Xanthium strumarium 15±3 rădăcină de maral, Rhaponticum carthamoides 16±3 coajă de nucă, Juglans regia 11±2 rădăcină de hrean, Armoracia rusticana 16±3 partea aeriană de leuştean, Levisticum officinale 16±3 propolis 11±2. aerial part of wormwood, Artemisia vulgaris 15±3 aerial part of cornel, Xanthium strumarium 15±3 maral root, Rhaponticum carthamoides 16±3 walnut shell, Juglans regia 11±2 horseradish root, Armoracia rusticana 16±3 aerial part of lovage, Levisticum officinale 16±3 propolis 11±2.
Rezultatul invenţiei constă în lărgirea gamei de suplimente alimentare fitoterapeutice, biologic active, care posedă activitate antioxidantă cu capacitatea de a inhiba radicalii liberi cu ulterioara reducere a acestora, imunostimulatoare cu inhibarea virusului SARS-CoV-2 şi care semnificativ micşorează durata însănătoşirii. The result of the invention consists in expanding the range of phytotherapeutic, biologically active food supplements, which possess antioxidant activity with the ability to inhibit free radicals with their subsequent reduction, immunostimulants with inhibition of the SARS-CoV-2 virus and which significantly reduce the duration of recovery.
Rezultatul se datorează selectării reuşite a componentelor cantitative şi calitative care manifestă un sinergism şi produc un efect antioxidant si imunostimulator pronunţat. The result is due to the successful selection of quantitative and qualitative components that exhibit synergism and produce a pronounced antioxidant and immunostimulatory effect.
Suplimentul alimentar fitoterapeutic, biologic activ are următoarele avantaje: The phytotherapeutic, biologically active food supplement has the following advantages:
- este simplu în tehnologia de preparare; - it is simple in preparation technology;
- este bazat pe fitoproduse autohtone; - it is based on local phytoproducts;
- nu necesită a fi prescris prin reţetă, deoarece nu reprezintă un medicament; - does not require a prescription, as it is not a medicine;
- are un efect polivalent - antioxidant sporit, imunostimulator cu inhibarea virusului SARS-CoV-2; - has a multivalent effect - increased antioxidant, immunostimulator with inhibition of the SARS-CoV-2 virus;
- reduce semnificativ termenele de însănătoşire. - significantly reduces recovery times.
Acţiunea antioxidantă a fost studiată în investigaţiile experimentale, efectuate asupra şobolanilor albi, linia Wistar, selectaţi conform principiului analogiei, după greutate, vârstă şi sex. Animalele experimentale au fost împărţite în două loturi a câte 36 de şobolani: lotul 1 (control), a primit doar raţie echilibrată de bază (RB) fără supliment alimentar; lotul 2 experimental - a primit o raţie similară (RB) + suplimentul alimentar biologic activ (SA) prezentat în calitate de invenţie. The antioxidant action was studied in experimental investigations, carried out on white rats, Wistar line, selected according to the principle of analogy, by weight, age and sex. The experimental animals were divided into two groups of 36 rats each: group 1 (control), received only a balanced basic ration (RB) without food supplement; experimental group 2 - received a similar ration (RB) + the biologically active food supplement (SA) presented as an invention.
Animalele din lotul 2 au primit suplimentul alimentar corespunzător în baza calculului de 1 ml/10 kg masă corporală. La animalele din lotul de control (1) şi lotul experimental (2), a fost determinat în sânge conţinutul glutationului oxidat şi a carnozinei, datele experimentale obţinute sunt incluse în tabelul 1. Animals in group 2 received the appropriate dietary supplement based on the calculation of 1 ml/10 kg body weight. In animals in the control group (1) and the experimental group (2), the content of oxidized glutathione and carnosine was determined in the blood, the experimental data obtained are included in table 1.
Tabelul 1 Table 1
Conţinutul glutationului oxidat şi a carnozinei la animalele loturilor martor şi experimental Oxidized glutathione and carnosine content in animals of the control and experimental groups
Loturile de animale Particularităţile alimentaţiei Indicii activităţii antioxidante Glutation oxidat, µmol/100mg Carnozină, µmol/100mg 1 (martor) Raţie de bază (RB) 35,11±2,41 32,02±1,34 2 (experimental) RB+SA conform invenţiei 28,37±1,06 43,21±1,19Animal groups Nutritional characteristics Antioxidant activity indices Oxidized glutathione, µmol/100mg Carnosine, µmol/100mg 1 (control) Basic ration (RB) 35.11±2.41 32.02±1.34 2 (experimental) RB+SA according to the invention 28.37±1.06 43.21±1.19
În calitate de criterii de evaluare a potenţialului antioxidant au fost luaţi indicii conţinutului glutationului oxidat şi a carnozinei. The indices of oxidized glutathione and carnosine content were taken as criteria for evaluating antioxidant potential.
Cu cât este mai scăzut nivelul glutationului oxidat, cu atât este mai mare nivelul glutationului redus şi cu atât potenţialul antioxidant al organismului este mai sporit, deoarece are un potenţial mai mare de neutralizare a radicalilor liberi. Astfel, cu cât nivelul glutationului oxidat este mai scăzut, cu atât potenţialul antioxidant este mai mare, respectiv 28,37±1,06 µmol/100mg conform invenţiei revendicate, comparativ cu 35,11±2,41 µmol/100mg în lotul de control. The lower the level of oxidized glutathione, the higher the level of reduced glutathione and the higher the antioxidant potential of the body, because it has a greater potential to neutralize free radicals. Thus, the lower the level of oxidized glutathione, the higher the antioxidant potential, respectively 28.37±1.06 µmol/100mg according to the claimed invention, compared to 35.11±2.41 µmol/100mg in the control group.
Glutationului îi revine un rol deosebit în protecţia antioxidantă a organismului. Potenţialul înalt de detoxificare al glutationului este determinat de conţinutul grupelor sulfhidrice (-SH), care absorb nu numai radicalii liberi, dar şi toxinele metabolice şi metalele grele. Enzimele sistemului antioxidant al organismului neutralizează circa 70% din oxidanţi şi substanţe toxice. Glutathione plays a special role in the antioxidant protection of the body. The high detoxification potential of glutathione is determined by the content of sulfide groups (-SH), which absorb not only free radicals, but also metabolic toxins and heavy metals. The enzymes of the body's antioxidant system neutralize about 70% of oxidants and toxic substances.
Conţinutul majorat al carnozinei la animalele lotului experimental, cărora li s-a administrat suplimentul revendicat, indică că se previne deteriorarea celulelor de acţiunea radicalilor liberi, deci suplimentul propus posedă proprietăţi antioxidante prin inhibarea producerii radicalilor liberi. The increased content of carnosine in the experimental group of animals, which were administered the claimed supplement, indicates that cell damage from the action of free radicals is prevented, therefore the proposed supplement possesses antioxidant properties by inhibiting the production of free radicals.
Totodată proprietăţile imunostimulatoare ale suplimentului alimentar revendicat au fost testate la pacienţii cu SARS-CoV-2 cu evoluţie medie a bolii (tabelele 2 şi 3). At the same time, the immunostimulating properties of the claimed food supplement were tested in patients with SARS-CoV-2 with average disease progression (tables 2 and 3).
Tabelul 2 Table 2
Influenţa terapiei cu suplimentul alimentar asupra dinamicii indicilor imunoglobulinelor la pacienţii cu infecţie SARS-CoV-2 în formă medie Influence of dietary supplement therapy on the dynamics of immunoglobulin indices in patients with moderate SARS-CoV-2 infection
Imunoglobulinele În ziua spitalizării Lotul experimental Lotul de control Ziua a 5-a Ziua a 14-a Ziua a 5-a Ziua a 14-a IgM 28,7±1,1 40,0±1,9 40,6±1,39 31,9±1,0 35,1±1,7 IgG 668,5±1,2 679,2±1,3 691,06±1,44 645,2±1,7 654,4±1,3 IgA 61,7±1,8 68,7±1,0 69,0±1,22 62,3±1,91 64,9±1,43Immunoglobulins On the day of hospitalization Experimental group Control group Day 5 Day 14 Day 5 Day 14 IgM 28.7±1.1 40.0±1.9 40.6±1.39 31.9±1.0 35.1±1.7 IgG 668.5±1.2 679.2±1.3 691.06±1.44 645.2±1.7 654.4±1.3 IgA 61.7±1.8 68.7±1.0 69.0±1.22 62.3±1.91 64.9±1.43
Pacienţii din lotul de control (41 persoane) au primit tratament conform protocolului adoptat la „Centrul COVID-19”. Lotul experimental (41 persoane), a primit suplimentul alimentar revendicat, în cantitate de 1 ml la 10 kg de greutate corporală, adjuvant ca tratament conform protocolului aprobat. Rezultatele cercetării sunt prezentate în tabelul 2. Datele obţinute indică faptul că suplimentul alimentar elaborat are un efect imunostimulator. Nivelul IgM la pacienţii care au primit suplimentul în a 5-a zi a fost de 40,0±1,9, comparativ cu 31,9±1,0 în lotul de control, adică în creştere. În ziua a 14-a, nivelul IgM în lotul experimental a fost de 40,6±1,39, faţă de 35,1±1,7 în lotul de control adică, la fel, în creştere. O tendinţă similară a fost observată în concentraţia de IgG şi IgA (tabelul 2). Patients in the control group (41 people) received treatment according to the protocol adopted at the “COVID-19 Center”. The experimental group (41 people) received the claimed food supplement, in the amount of 1 ml per 10 kg of body weight, as an adjuvant treatment according to the approved protocol. The results of the research are presented in Table 2. The data obtained indicate that the developed food supplement has an immunostimulating effect. The IgM level in patients who received the supplement on the 5th day was 40.0±1.9, compared to 31.9±1.0 in the control group, i.e. increasing. On the 14th day, the IgM level in the experimental group was 40.6±1.39, compared to 35.1±1.7 in the control group, i.e. also increasing. A similar trend was observed in the concentration of IgG and IgA (Table 2).
Dinamica semnelor clinice la pacienţii cu diagnostic de SARS-CoV-2, formă medie, trataţi cu suplimentul biologic activ revendicat pe un lot de 82 de pacienţi, dintre care 41 (grupul de studiu) şi 41 (grupul de control) este reprezentată în tabelul 3. The dynamics of clinical signs in patients diagnosed with SARS-CoV-2, moderate form, treated with the claimed biologically active supplement in a group of 82 patients, of which 41 (study group) and 41 (control group) is represented in Table 3.
Tabelul 3 Table 3
Semnele clinice Grupul de studiu Grupul de control La momentul adresării, nr. pacienţi În a 5-a zi a tratamentului În a 14-a zi a tratamen-tului La momentul adresării, nr. pacienţ În a 5-a zi a tratamentului În a 14-a zi a tratamentului 1. Starea generală 2. Temperatura 3. Rinoree, lipsa mirosului şi gustului 4. Dureri în gât 5. Tuse uscată 6. Disfuncţii respiratorii 7. Dureri în piept 41 satisf. 41 (37,6±0,02) 15 8 5 8 FR≤25±1 5 41 satisf. 41(36,6±0,02) - - - 41 FR≤22±1 - - - - - - - - 41 satisf. 41(37,3±0,04) 16 7 6 8 FR≤26±1 4 41 satisf. 41(37,1±0,02) 16 7 6 8 FR≤25±1 4 41 satisf. 41 (36,7±0,01) - - - 41 FR≤23±1 -Clinical signs Study group Control group At the time of referral, no. patients On the 5th day of treatment On the 14th day of treatment At the time of referral, no. patients On the 5th day of treatment On the 14th day of treatment 1. General condition 2. Temperature 3. Rhinorrhea, loss of smell and taste 4. Sore throat 5. Dry cough 6. Respiratory dysfunction 7. Chest pain 41 satis. 41 (37.6±0.02) 15 8 5 8 FR≤25±1 5 41 satis. 41(36.6±0.02) - - - 41 FR≤22±1 - - - - - - - - 41 satis. 41(37.3±0.04) 16 7 6 8 FR≤26±1 4 41 satis. 41(37.1±0.02) 16 7 6 8 FR≤25±1 4 41 satisfied. 41 (36.7±0.01) - - - 41 FR≤23±1 -
Rezultatele obţinute demonstrează convingător activitatea antivirală sporită a suplimentului biologic activ elaborat împotriva virusului SARS-CoV-2. The results obtained convincingly demonstrate the enhanced antiviral activity of the developed biologically active supplement against the SARS-CoV-2 virus.
Exemplu de realizare a invenţiei Example of embodiment of the invention
Pacientul A., vârsta de 54 ani, internat la Centrul COVID-19, la internare: starea generală-satisfăcătoare, temperatura - 37,6°C, rinoree, lipsa mirosului şi gustului, dureri în gât, tuse uscată, disfuncţii respiratorii - FR 26, dureri în piept, testul la SARS-CoV-2 - pozitiv (prin testare din nazo- şi orofaringe). După administrarea suplimentului fitoterapeutic biologic activ timp de 5 zile toate semnele clinice au dispărut, iar testul la SARS-CoV-2 - negativ (prin testare din nazo- şi orofaringe). Patient A., 54 years old, admitted to the COVID-19 Center, upon admission: general condition - satisfactory, temperature - 37.6°C, rhinorrhea, loss of smell and taste, sore throat, dry cough, respiratory dysfunction - FR 26, chest pain, SARS-CoV-2 test - positive (by testing from the naso- and oropharynx). After administering the biologically active phytotherapeutic supplement for 5 days, all clinical signs disappeared, and the SARS-CoV-2 test - negative (by testing from the naso- and oropharynx).
Modul de preparare a suplimentului alimentar este următorul: componentele suplimentului: partea aeriană de pelin (Artemisia vulgaris), partea aeriană de cornet (Xanthium strumarium), rădăcina de maral (Rhaponticum carthamoides), coaja de nucă (Juglans regia), rădăcina de hrean (Armoracia rusticana), partea aeriană de leuştean (Levisticum officinale) şi propolisul, în raportul revendicat, se infuzează pe bază de alcool de 96,4% vol., într-un raport respectiv de 1:4-1:5, timp de 15-21 de zile, cu agitare zilnică, după care se adaugă apă purificată până la obţinerea soluţiei hidroalcoolice de 32-35% vol., se pune la răcire în frigider la temperatura de 8-9°C pentru precipitare, se decantează şi se filtrează. După care suplimentul obţinut este gata de utilizare. The method of preparation of the food supplement is as follows: the components of the supplement: the aerial part of wormwood (Artemisia vulgaris), the aerial part of cornel (Xanthium strumarium), the root of maral (Rhaponticum carthamoides), the shell of walnut (Juglans regia), the root of horseradish (Armoracia rusticana), the aerial part of lovage (Levisticum officinale) and propolis, in the claimed ratio, are infused on a 96.4% vol. alcohol basis, in a respective ratio of 1:4-1:5, for 15-21 days, with daily stirring, after which purified water is added until a 32-35% vol. hydroalcoholic solution is obtained, it is cooled in the refrigerator at a temperature of 8-9°C for precipitation, it is decanted and filtered. After which the supplement obtained is ready for use.
Datele experimentale obţinute demonstrează că suplimentul alimentar propus asigură creşterea potenţialului antioxidant, imunostimulator şi antiviral al organismului. The experimental data obtained demonstrate that the proposed dietary supplement ensures an increase in the antioxidant, immunostimulatory and antiviral potential of the body.
Exemplu concret de preparare a suplimentului alimentar fitoterapeutic: se selectează ingredientele, se mărunţesc, se amestecă după cum urmează, în % mas.: partea aeriană de pelin 15, partea aeriană de cornet 15, rădăcină de maral 16, coajă de nucă 11, rădăcină de hrean 16, partea aeriană de leuştean 16 şi propolis 11. Amestecul se infuzează pe bază de alcool de 96,4% vol., într-un raport respectiv de 1:4, timp de 15 de zile, cu agitare zilnică, se adaugă apă purificată până la obţinerea soluţiei hidroalcoolice de 35% vol., se pune la răcire în frigider la temperatura de 8°C pentru precipitare, se decantează şi se filtrează. Concrete example of preparation of the phytotherapeutic food supplement: select the ingredients, chop them, mix them as follows, in % by weight: wormwood aerial part 15, cornel aerial part 15, maral root 16, walnut shell 11, horseradish root 16, lovage aerial part 16 and propolis 11. The mixture is infused on a 96.4% vol. alcohol basis, in a respective ratio of 1:4, for 15 days, with daily stirring, purified water is added until a 35% vol. hydroalcoholic solution is obtained, it is cooled in the refrigerator at a temperature of 8°C for precipitation, it is decanted and filtered.
Suplimentul poate fi recomandat pentru includerea în componenţa produselor alimentare fitoterapeutice predestinate sporirii potenţialului imunostimulator, antiviral şi antioxidant ale organismului şi prescris în tratarea infecţiei SARS-CoV-2. Tehnologia de pregătire a suplimentului alimentar este accesibilă şi necostisitoare. Suplimentul alimentar, fitoterapeutic biologic activ, se administrează de 3 ori pe zi, per os, cu 15 min înainte de masă, câte 50 ml, timp de 5 zile. The supplement can be recommended for inclusion in the composition of phytotherapeutic food products intended to increase the immunostimulatory, antiviral and antioxidant potential of the body and prescribed in the treatment of SARS-CoV-2 infection. The technology for preparing the food supplement is accessible and inexpensive. The biologically active phytotherapeutic food supplement is administered 3 times a day, orally, 15 minutes before meals, 50 ml each, for 5 days.
1. RU 2366411 C2 2009.09.10 1. RU 2366411 C2 2009.09.10
2. RU 2505306 C2 2014.01.27 2. RU 2505306 C2 2014.01.27
3. RU 2731932 C1 2020.09.09 3. RU 2731932 C1 2020.09.09
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20200126A MD1531Z (en) | 2020-10-09 | 2020-10-09 | Phytotherapeutic food supplement antiSARS-CoV-2 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20200126A MD1531Z (en) | 2020-10-09 | 2020-10-09 | Phytotherapeutic food supplement antiSARS-CoV-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1531Y MD1531Y (en) | 2021-05-31 |
| MD1531Z true MD1531Z (en) | 2021-12-31 |
Family
ID=76191337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20200126A MD1531Z (en) | 2020-10-09 | 2020-10-09 | Phytotherapeutic food supplement antiSARS-CoV-2 |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1531Z (en) |
-
2020
- 2020-10-09 MD MDS20200126A patent/MD1531Z/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD1531Y (en) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ndhlala et al. | Toxicology of some important medicinal plants in southern Africa | |
| US6576267B2 (en) | Composition and method for treating the effects of diseases and maladies | |
| EP3412292B1 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
| CN100553665C (en) | A kind of Chinese medicine medicine for the treatment of pharyngolaryngitis | |
| TW201827044A (en) | Composition for treating inflammatory bowel disease | |
| MD1531Z (en) | Phytotherapeutic food supplement antiSARS-CoV-2 | |
| MD1533Z (en) | Phytotherapeutic food supplement anti-SARS-CoV-2 | |
| MD1532Z (en) | Phytotherapeutic food supplement anti-SARS-CoV-2 | |
| Watson | Some observations on the effect of blueberry leaf extract in diabetes mellitus | |
| JP2008247779A (en) | Antiallergic food and antiallergic external preparation | |
| MD1629Z (en) | Anti-SARS-CoV-2 phytotherapeutic food additive | |
| CN105451749B (en) | Adsorb drone larvae homogenate and the application of vitamine D3 or D family vitamin and/or its active metabolite in the prevention and treatment of viral disease | |
| RU2410096C1 (en) | Method of treating patients suffering psoriasis combined with chronic opisthorchosis | |
| EP0722325A1 (en) | Composition for the treatment or prevention of herpes | |
| Dubey et al. | Acute renal failure: a complication of Datura poisoning | |
| MD1541Z (en) | Method for treating infections with SARS-CoV-2 virus of medium form | |
| CN113476438B (en) | Hypoglycemic composition containing dihydromorin and its application | |
| RU2776878C1 (en) | Method for combined treatment of tick typhus caused by heilongjiang rickettsia, organic selenium | |
| JP2009263384A (en) | Internal medicine for inhibiting symptom of atopic dermatitis of type i allergic disorder | |
| JP2024083774A (en) | supplement | |
| Sahu et al. | Natural Bioactives used for Meningitis | |
| CN116392476A (en) | Composition for synergistically inhibiting pancreatic lipase and application thereof | |
| Joshi et al. | Role of Vitamin-C, Vitamin-D and Zinc in Covid-19 Pandemic | |
| Douglas | Nuclein in a Case of Malignant Disease, with a Note on the Uric Acid Excretion | |
| UA148159U (en) | METHOD OF MANUFACTURE OF DRUG (DIETARY SUPPLEMENT) "THYROCLINE" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |